CV205-502 is a new non-ergot
dopamine agonist currently being studied for the treatment of
hyperprolactinaemia. We have assessed the effects of
CV205-502 on
prolactin secretion and the clinical consequences of
hyperprolactinaemia in 16 patients with
hyperprolactinaemia who had previously been unsuccessfully treated with
bromocriptine. These patients had been either intolerant of and/or resistant to the effects of
bromocriptine. Sixteen patients, all women in an age range between 20 and 49 years (mean 31.5 years), were treated for periods of between 8 and 52 weeks with doses of
CV205-502 ranging from 0.075 to 0.3 mg taken once daily at night. Seven out of 10 of the patients, who were intolerant of
bromocriptine, tolerated
CV205-502 better with fewer side effects although the nature of the side effects was similar to that associated with
bromocriptine. Only 1 patient from this group stopped taking
CV205-502 due to side effects. Six of 11 patients exhibiting
bromocriptine resistance showed a significant reduction in the degree of
hyperprolactinaemia but normoprolactinaemia was achieved in only 1. Galactorrhoea ceased in 2 of 6 patients, menstruation resumed in 6 of 11 patients presenting with amenorrhoea, and 2 patients conceived. In patients with
bromocriptine intolerance and/or resistance,
CV205-502 is useful as a second line treatment.